By Adriano Marchese

Moderna is restructuring its organization and leadership in preparation for a new wave of product launches, expanding President Stephen Hoge's role and appointing longtime pharma executive Ester Banque as chief commercial officer.

Under the restructuring, Hoge will oversee research and development, manufacturing and commercial operations to coordinate work as Moderna moves to shift from a single-product Covid-19 vaccine maker to a diversified, multimodality biotechnology company.

The company expects to launch into the new products. Moderna is preparing for potential launches of flu-Covid-19 combination shot, a seasonal flu vaccine, and a norovirus vaccine in 2027 and 2028, alongside possible first approvals in oncology and rare diseases.

As part of the changes, the company is appointing Banque to the role of CCO as it continues to build its commercial capabilities, launch new products and expand into new markets, it said Tuesday.

She most recently served as executive vice president and president of Zoetis' U.S. operations, and as senior vice president and general manager of Bristol Myer Squibb's U.S. hematology and cell therapy business.

Prior to that, she served at Novartis, holding leadership roles of increasing responsibility.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

June 16, 2026 08:58 ET (12:58 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.